MAPT and Alzheimer disease: AD biomarker (PET, CSF, plasma) and MRS studies suggest that the association of 1H MRS with Aβ and/or tau pathology may vary based on the AD stage and the topographical heterogeneity of the disease, with these associations being region-specific.